Log in

Mateon Therapeutics News Headlines (OTCMKTS:MATN)

$0.20
0.00 (0.00 %)
(As of 12/13/2019 04:00 PM ET)
Today's Range
$0.19
Now: $0.20
$0.21
50-Day Range
$0.18
MA: $0.22
$0.27
52-Week Range
$0.05
Now: $0.20
$0.35
Volume12,390 shs
Average Volume32,142 shs
Market Capitalization$16.61 million
P/E RatioN/A
Dividend YieldN/A
Beta2.98

Headlines

Mateon Therapeutics (OTCMKTS MATN) News Headlines

Source:
DateHeadline
Mateon Therapeutics Inc. (MATN) SEC FilingsMateon Therapeutics Inc. (MATN) SEC Filings
www.nasdaq.com - December 12 at 7:04 PM
Steven King Named as Prospective CEO of EdgePoint AISteven King Named as Prospective CEO of EdgePoint AI
finance.yahoo.com - December 11 at 12:41 PM
Mateon Therapeutics Team Publishes Three New Peer-Reviewed Oncology Articles Outlining the Clinical Impact Potential of Its First-In-Class Anti-TGF-Beta RNA Therapeutic OT101/TrabedersenMateon Therapeutics Team Publishes Three New Peer-Reviewed Oncology Articles Outlining the Clinical Impact Potential of Its First-In-Class Anti-TGF-Beta RNA Therapeutic OT101/Trabedersen
finance.yahoo.com - December 2 at 1:05 PM
Mateon Therapeutics to Present New and Updated Data for OT101 (Trabedersen) Activity Against Brain Tumors at the 2019 Society for Neuro-Oncology (SNO) Annual MeetingMateon Therapeutics to Present New and Updated Data for OT101 (Trabedersen) Activity Against Brain Tumors at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting
finance.yahoo.com - November 18 at 1:13 PM
Mateon completes its acquisition of PointR Data Inc.Mateon completes its acquisition of PointR Data Inc.
finance.yahoo.com - November 4 at 2:07 PM
New Research Study Provides Target Validation for Mateon’s First-in-Class RNA Therapeutic OT101 for the Treatment of Difficult to Treat Forms of Childhood Brain TumorNew Research Study Provides Target Validation for Mateon’s First-in-Class RNA Therapeutic OT101 for the Treatment of Difficult to Treat Forms of Childhood Brain Tumor
finance.yahoo.com - October 23 at 1:14 PM
MATN.PK - Mateon Therapeutics Inc Profile | ReutersMATN.PK - Mateon Therapeutics Inc Profile | Reuters
www.reuters.com - October 9 at 8:23 PM
FDA Grants Pediatric Disease Designation for Mateon’s OT101FDA Grants Pediatric Disease Designation for Mateon’s OT101
finance.yahoo.com - September 23 at 3:35 PM
Mateon and PointR Data merge to form artificial intelligence driven immuno-oncology companyMateon and PointR Data merge to form artificial intelligence driven immuno-oncology company
seekingalpha.com - August 19 at 6:47 PM
Mateon Enters into Merger Agreement with PointR Data to Leverage Disruptive AI Technology in Its Innovation-Driven Quest for a Cure of CancerMateon Enters into Merger Agreement with PointR Data to Leverage Disruptive AI Technology in Its Innovation-Driven Quest for a Cure of Cancer
finance.yahoo.com - August 19 at 9:21 AM
Oncotelic’s Patented Lead Anti-Cancer Drug Candidate as Well as Drug Delivery Platform for Brain Tumors on Track for Advanced Pivotal Phase 3 Clinical TestingOncotelic’s Patented Lead Anti-Cancer Drug Candidate as Well as Drug Delivery Platform for Brain Tumors on Track for Advanced Pivotal Phase 3 Clinical Testing
finance.yahoo.com - July 30 at 6:47 PM
Internationally Recognized Top Neurosurgeon Joins the Medical Advisory Board of OncotelicInternationally Recognized Top Neurosurgeon Joins the Medical Advisory Board of Oncotelic
finance.yahoo.com - July 16 at 6:06 PM
Oncotelic Appoints Four Eminent Physician-Scientists Internationally Recognized for their Work in Oncology and Immunology to Newly Established Medical Advisory BoardOncotelic Appoints Four Eminent Physician-Scientists Internationally Recognized for their Work in Oncology and Immunology to Newly Established Medical Advisory Board
finance.yahoo.com - June 12 at 12:18 PM
Mateon and Oncotelic Report on Continuing Integration of the two BusinessesMateon and Oncotelic Report on Continuing Integration of the two Businesses
finance.yahoo.com - June 10 at 10:03 AM
Mateon Reports First Quarter 2019 Financial ResultsMateon Reports First Quarter 2019 Financial Results
finance.yahoo.com - May 15 at 7:06 PM
Mateon completes Oncotelic tie-upMateon completes Oncotelic tie-up
seekingalpha.com - April 25 at 9:17 AM
Mateon and Oncotelic Complete Their Merger and Create a New Immuno-Oncology Company with a Late-Stage Clinical Asset Against Cancer and a Promising Product PipelineMateon and Oncotelic Complete Their Merger and Create a New Immuno-Oncology Company with a Late-Stage Clinical Asset Against Cancer and a Promising Product Pipeline
finance.yahoo.com - April 25 at 9:17 AM
Mateon Enters into Merger Agreement with OncotelicMateon Enters into Merger Agreement with Oncotelic
finance.yahoo.com - April 18 at 9:25 AM
Mateon Therapeutics, Inc. (MATN)Mateon Therapeutics, Inc. (MATN)
finance.yahoo.com - April 1 at 6:46 PM
This page was last updated on 12/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel